SHIPi Enhances Autologous and Allogeneic Hematolymphoid Stem Cell Transplantation.

ABSTRACT: Hematopoietic stem cell transplantation (HSCT) is a highly effective procedure enabling long-term survival for patients with hematologic malignancy or heritable defects. Although there has been a dramatic increase in the success rate of HSCT over the last two decades, HSCT can result in serious, sometime untreatable, disease due to toxic conditioning regimens, graft vs. host disease and required use of mismatched bone marrow in some cases. Studies utilizing germline knockout mice have discovered several candidate genes that could be targeted pharmacologically to create a more favorable environment for transplant success. SHIP1 deficiency permits improved engraftment of hematopoietic stem-progenitor cells (HS-PC) and produces a suppressive microenvironment ideal for incoming grafts. The rec

SUBMITTER: Fernandes S 

PROVIDER: S-EPMC4452032 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature